MedTrace Logo

A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies

NCT02503033 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2020-09-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of HMPL-523 administered to patients with relapsed or refractory Hematologic Malignancies

To determine the maximum tolerated dosage/recommended phase 2 dosage and characterize the dose limited toxicities associated with HMPL-523 when administered to patients with relapsed or refractory Hematologic Malignancies

Conditions

Interventions

DRUG

HMPL-523

Oral administration, once daily

Sponsors & Collaborators

  • Iqvia Pty Ltd

    collaborator INDUSTRY

  • Hutchison Medipharma Limited

    lead INDUSTRY

Principal Investigators

  • Chen Yu, MD · Hutchison Medi Pharma

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2020-12-31
Completion
2021-03-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02503033 on ClinicalTrials.gov